Wydanie specjalne czerw 2018
str. 5 - 7

Ranibizumab w Programie Lekowym – analiza wyników leczenia neowaskularnej postaci zwyrodnienia plamki związanego z wiekiem wg schematu pro re nata

Ranibizumab in Drug Prescription Program – Analysis of the Treatment Results of the Neovascular Age-related Macular Degeneration in PRN Scheme

Andrzej Stankiewicz, Dagmara Dziurkowska

Klinika Okulistyczna MAVIT w Katowicach
Kierownik: prof. dr hab. n. med. Andrzej Stankiewicz


Summary: Purpose: The purpose of the study was to evaluate the visual and anatomical function in patients who received pro re nata injections of ranibizumab.
Material and Methods: The retrospective study include 128 patients (133 eyes) with exudative age- related macular degeneration treated with ranibizumab. Ophthalmological examination included fluoresceine angiography and spectral domain optical coherence tomography.
Results: In 17-month period visual acuity improved from mean 0.4 to 0.56 on the Snellen charts. A significant decrease in maximum central retinal thickness was noticed after treatment – mean 385.8 mm at baseline and mean 258.4 mm at the end of observation period. The patients received on average 4.9 injections/ 17 month period.
Conclusions: Treatment of exudative age-related macular degeneration with ranibizumab injections in pro re nata scheme was associated with anatomical and visual acuity improvement.

Słowa kluczowe: wysiękowa postać zwyrodnienia plamki związanego z wiekiem, ranibizumab, leczenie „według potrzeb”.

Keywords: exudative age-related macular degeneration, ranibizumab, pro re nata therapy.


powrót

REDAKCJA NIE UDZIELA PORAD MEDYCZNYCH I NIE POŚREDNICZY W KONSULTACJACH PACJENTÓW Z LEKARZAMI